Multiple Sclerosis Drugs Market size worth $ 42.46 Billion, Globally, by 2028 at 6.3% CAGR: Verified Market Research®

The expansion of the multiple sclerosis drugs market is encouraged by government and non-government organizations, Clinical studies for the treatment of multiple sclerosis are key factors driving the growth of the market.

JERSEY CITY, N.J., Aug. 10, 2021 /PRNewswire/ -- Verified Market Research recently published a report, "Multiple Sclerosis Drugs Market" By Type (Immunosuppressants and Immunomodulators), By Administration (Oral, Injectable, and Intravenous), and By Geography. According to Verified Market Research, the Global Multiple Sclerosis Drugs Market size was valued at USD 27.47 Billion in 2020 and is projected to reach USD 42.46 Billion in 2028, growing at a CAGR of 6.3% from 2021-2028.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=180077

Browse in-depth TOC on "Multiple Sclerosis Drugs Market"

202 - Pages

126 – Tables

37 – Figures

Global Multiple Sclerosis Drugs Market Overview

The expansion of the Multiple Sclerosis Drugs Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).In 2020, The World Health Organization (WHO) released an Essential Medicines List (EML)  as currently no drugs on the EML that are indicated for multiple sclerosis (MS). The Multiple Sclerosis International Federation (MSIF) prepared an application to include disease-modifying treatments for MS (DMTs), in collaboration with the Regional Committees for Treatment and Research in Multiple Sclerosis (TRIMS) and the World Federation of Neurology, for the 2019 EML.

MS affects about 2.5 million individuals worldwide, causing major morbidity and cost to healthcare systems. DMTs have been shown to change the course of MS, and their inclusion on the WHO EML would be a valuable weapon for advocacy efforts to promote access to therapy in many countries providing direction to healthcare institutions on how to deliver a portfolio of medicines that would allow the vast majority of MS patients to be adequately treated. The task force recommended glatiramer acetate, fingolimod, and ocrelizumab for WHO consideration after thorough discussion and analysis of the evidence.

In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.

Key Developments in Multiple Sclerosis Drugs Market

• In August 2020, Genzyme Corporation agreed to buy Principia Biopharma Inc., a firm that develops therapy solutions for immune-mediated diseases. This acquisition added the company's research endeavors in the field of multiple sclerosis, as well as other immune-mediated diseases.
• In July 2019, Copaxone (glatiramer acetate injection) is now available in the prefilled autoinjector YpsoMate from Teva Pharmaceuticals USA, Inc. This launch assisted patients in managing medicine doses and allowing them to give drug doses without the assistance of a drug administrator. This strategy improved the product portfolio and increased income.

The major players in the market are Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA).

Verified Market Research has segmented the Global Multiple Sclerosis Drugs Market On the basis of Type, Administration, and Geography`.

• Multiple Sclerosis Drugs Market, By Type
• Immunosuppressants
• Immunomodulator
  
• Multiple Sclerosis Drugs Market, By Route of Administration
• Oral
• Injectable
• Intravenous
  
• Multiple Sclerosis Drugs Market by Geography
• North America
• U.S
• Canada
• Mexico
• Europe
• Germany
• France
• U.K
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• ROW
• Middle East & Africa
• Latin America

Browse Related Reports:

Autoimmune Disease Therapeutics Market By Drug (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Anti-inflammatory, Interferons, Antihyperglycemics), By Disease (Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Type 1 Diabetes), By Geography, Forecast, 2020-2027

Neurorehabilitation Devices Market By Product (Brain-computer Interface, Neurorobotic Systems, Brain Stimulators, Wearable Devices), By Application (Brain & Spinal Cord Injury, Stroke, Multiple Sclerosis, Parkinson's Disease), By Geography, Forecast, 2020-2027

Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Treatment (Medication, Stem Cell Therapy, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By Geography, Forecast, 2020-2027

Photodynamic Therapy Market By Product (Photosensitizer Drug and Photodynamic Therapy Devices), By Application (Cancer, Actinic Keratosis, Psoriasis), By End-User (Hospitals, Cancer Treatment Centers), By Geography, Forecast, 2020-2027

Understanding the COVID-19 Impact on Healthcare Industry

Visualize Multiple Sclerosis Drugs Market using Verified Market Intelligence:-:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us

Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1315349/Verified_Market_Research_Logo.jpg